Literature DB >> 26660190

Development of an Assay for Methotrexate and Its Metabolites 7-Hydroxy Methotrexate and DAMPA in Serum by LC-MS/MS.

Ryan C Schofield1, Lakshmi V Ramanathan1, Kazunori Murata1, Martin Fleisher1, Melissa S Pessin1, Dean C Carlow2.   

Abstract

Methotrexate (MTX) is a folic acid antagonist that is widely used as an immunosuppressant and chemotherapeutic agent. After high-dose administration of MTX serum levels must be monitored to determine when to administer leucovorin, a folic acid analog that bypasses the enzyme inhibition caused by MTX and reverses its toxicity. We describe a rapid and simple turbulent flow liquid chromatography (TFLC) method implementing positive heated electrospray ionization (HESI) for the accurate and precise determination of MTX, 7-hydroxymethotrexate (7-OH MTX), and 4-amino-4-deoxy-N(10)-methylpteroic acid (DAMPA) concentrations in serum. MTX is isolated from serum samples (100 μL) after protein precipitation with a methanolic solution containing internal standard (MTX-D3) followed by centrifugation. The supernatant is injected into the turbulent flow liquid chromatography which is followed by electrospray positive ionization tandem mass spectrometry (TFLC-ESI-MS/MS) and quantified using a six-point calibration curve. For MTX, 7-OH MTX, and DAMPA the assays were linear from 20 to 1000 nmol/L. Dilutions of 10-, 100-, and 1000-fold were validated giving a clinically reportable range of 20 to 1.0 × 10(6) nmol/L. Within-day and between-day precisions at concentrations spanning the analytical measurement ranges were less than 10 % for all three analytes.

Entities:  

Keywords:  Carboxypeptidase-G2; Mass spectrometry; Methotrexate; Therapeutic drug monitoring; Turbulent flow liquid chromatography

Mesh:

Substances:

Year:  2016        PMID: 26660190     DOI: 10.1007/978-1-4939-3252-8_23

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study.

Authors:  Lauren R Schaff; Mina Lobbous; Dean Carlow; Ryan Schofield; Igor T Gavrilovic; Alexandra M Miller; Jacqueline B Stone; Anna F Piotrowski; Ugur Sener; Anna Skakodub; Edward P Acosta; Kevin J Ryan; Ingo K Mellinghoff; Lisa M DeAngelis; Louis B Nabors; Christian Grommes
Journal:  BMC Cancer       Date:  2022-01-13       Impact factor: 4.430

2.  Pharmacokinetics, bioavailability, and plasma protein binding study of glytrexate, a novel multitarget antifolate.

Authors:  Jiahong Xiang; Mengqi Wu; Jianchao Wang; Mengmeng Lin; Mengmeng Sun; Xin Li; Ruijuan Xing; Ran Guo; Jianmin Gu; Tao Lyu; Lei Wang; Xiaowei Shi
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.